Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Individual TF‐CBT vs Brief PTSD psychoeducation Health economics · Adults with co‐morbid PTSD and SMI Psychological interventions for post‐traumatic stress disorder (PTSD) in people with severe mental illness (2017) · Cochrane | no estimate extracted | NR | No studies |
Individual TF‐CBT vs waiting list/usual care Health economics · Adults with co‐morbid PTSD and SMI Psychological interventions for post‐traumatic stress disorder (PTSD) in people with severe mental illness (2017) · Cochrane | no estimate extracted | NR | No studies |
EMDR vs waiting list/usual care Quality of life: 1. General quality of life · Adults with co‐morbid PTSD and SMI Psychological interventions for post‐traumatic stress disorder (PTSD) in people with severe mental illness (2017) · Cochrane | no estimate extracted | NR | No studies |
Psychological interventions vs usual care Diabetes‐related complications Psychological interventions for diabetes‐related distress in adults with type 2 diabetes mellitus (2017) · Cochrane | no estimate extracted | NR | No studies |
Digital intervention vs face‐to‐face intervention Adverse events · s Personalised digital interventions for reducing hazardous and harmful alcohol consumption in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Digital intervention vs no or minimal intervention Adverse events · s Personalised digital interventions for reducing hazardous and harmful alcohol consumption in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Digital intervention vs face‐to‐face intervention Intensity of drinking (g/drinking day) · s Personalised digital interventions for reducing hazardous and harmful alcohol consumption in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Assessment vs direct admission Neonatal admission to special care · healthy pregnant women Assessment and support during early labour for improving birth outcomes (2017) · Cochrane | no estimate extracted | NR | No studies |
Nutrition support vs no intervention, placebo, or treatment All‐cause mortality · hospitalised adults at nutritional risk Nutrition support in hospitalised adults at nutritional risk (2017) · Cochrane | no estimate extracted | NR | No studies |
Nutrition support vs no intervention, placebo, or treatment Serious adverse events · hospitalised adults at nutritional risk Nutrition support in hospitalised adults at nutritional risk (2017) · Cochrane | no estimate extracted | NR | No studies |
Peripheral nerve blocks vs systemic analgesia Total number of nerve block‐related complications · adults undergoing elective primary total hip replacement Nerve blocks or no nerve blocks for pain control after elective hip replacement (arthroplasty) surgery in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Interventions · people undergoing liver transplantation Maintenance immunosuppression for adults undergoing liver transplantation: a network meta‐analysis (2017) · Cochrane | no estimate extracted | NR | No studies |
Thiazolidinediones vs no intervention Health‐related quality of life · participants with non‐alcohol related fatty liver disease (NAFLD) Pharmacological interventions for non‐alcohol related fatty liver disease (NAFLD) (2017) · Cochrane | no estimate extracted | NR | No studies |
Antioxidants vs no intervention Health‐related quality of life · participants with non‐alcohol related fatty liver disease (NAFLD) Pharmacological interventions for non‐alcohol related fatty liver disease (NAFLD) (2017) · Cochrane | no estimate extracted | NR | No studies |
Bile acids vs no intervention Health‐related quality of life · participants with non‐alcohol related fatty liver disease (NAFLD) Pharmacological interventions for non‐alcohol related fatty liver disease (NAFLD) (2017) · Cochrane | no estimate extracted | NR | No studies |
Interferon vs no intervention Progression to fulminant HBV infection · people with acute HBV infection Pharmacological interventions for acute hepatitis B infection (2017) · Cochrane | no estimate extracted | NR | No studies |
Interferon vs no intervention Adverse events (number of events) · people with acute HBV infection Pharmacological interventions for acute hepatitis B infection (2017) · Cochrane | no estimate extracted | NR | No studies |
Lamivudine vs no intervention Progression to fulminant HBV infection · people with acute HBV infection Pharmacological interventions for acute hepatitis B infection (2017) · Cochrane | no estimate extracted | NR | No studies |
Lamivudine vs no intervention Health‐related quality of life (1 week) · people with acute HBV infection Pharmacological interventions for acute hepatitis B infection (2017) · Cochrane | no estimate extracted | NR | No studies |
Interferon vs no intervention Short‐term mortality · people with acute HBV infection Pharmacological interventions for acute hepatitis B infection (2017) · Cochrane | no estimate extracted | NR | No studies |
Interferon vs no intervention Progression to chronic HBV infection · people with acute HBV infection Pharmacological interventions for acute hepatitis B infection (2017) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline vs no intervention Health‐related quality of life · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Serious adverse events (number) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Health‐related quality of life · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Insulin plus glucagon vs no intervention Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Insulin plus glucagon vs no intervention Serious adverse events (number) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Insulin plus glucagon vs no intervention Health‐related quality of life · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Serious adverse events (number) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Health‐related quality of life · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Glucocorticosteroids vs no intervention Serious adverse events (number) · participants with severe alcoholic hepatitis Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Glucocorticosteroids vs no intervention Health‐related quality of life · participants with severe alcoholic hepatitis Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline vs no intervention Serious adverse events (number) · participants with severe alcoholic hepatitis Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline vs no intervention Health‐related quality of life · participants with severe alcoholic hepatitis Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Anabolic steroids vs no intervention Early mortality (mortality up to 90 days) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Anabolic steroids vs no intervention Serious adverse events (proportion) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Anabolic steroids vs no intervention Serious adverse events (number) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Glucocorticosteroids vs no intervention Serious adverse events (number) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Anabolic steroids vs no intervention Health‐related quality of life · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Antioxidants vs no intervention Early mortality (mortality up to 90 days) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Antioxidants vs no intervention Serious adverse events (proportion) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Antioxidants vs no intervention Serious adverse events (number) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Antioxidants vs no intervention Health‐related quality of life · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Early mortality (mortality up to 90 days) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Serious adverse events (proportion) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Serious adverse events (number) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Glucocorticosteroids vs no intervention Health‐related quality of life · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Health‐related quality of life · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |